CohBar’s First Mitochondria Based Therapy Shows Promise In NASH
New Modality In Hard-To-Crack Field
Executive Summary
The first clinical results from its mitochondrial derived peptide pipeline is good news for CohBar, but it needs investors or big pharma partners to help it progress.